Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT -1.67% Days Sales Outstanding is 70.76 as of Dec. 2025, which is 8% below its 10-year median of 76.57. The stock has 8 warning signs investors should review. Among 655 Healthcare Providers & Services companies, Resonance Health ranks worse than 77.71% on this metric.
The historical rank and industry rank for Resonance Health's Days Sales Outstanding or its related term are showing as below:
ASX:RHT'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.23 Med: 76.57 Max: 89.1
Current: 82.59
During the past 13 years, Resonance Health's highest Days Sales Outstanding was 89.10. The lowest was 62.23. And the median was 76.57.
ASX:RHT's Days Sales Outstanding is ranked worse than 77.71% of 655
companies
in the Healthcare Providers & Services industry
Industry Median: 47.19
vs ASX:RHT: 82.59
Resonance Health's Days Sales Outstanding
declined
from Dec. 2024 (97.38) to Dec. 2025 (70.76).
Resonance Health (ASX:RHT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Resonance Health Days Sales Outstanding Related Terms
Resonance Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Resonance Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, HQY: Days Sales Outstanding Comparison
For the Health Information Services subindustry, Resonance Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Resonance Health's Days Sales Outstanding falls into.
Resonance Health Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Days Sales Outstanding of 70.76 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Resonance Health and its competitors. This is near median its historical median of 76.57. Over the past decade, Resonance Health's Days Sales Outstanding has ranged from 62.23 to 89.10. According to the industry distribution chart, Resonance Health ranks #509 out of 655 companies in the Healthcare Providers & Services industry, placing it in the top 77.7%.
Is Resonance Health's Days Sales Outstanding too high?
Resonance Health's current Days Sales Outstanding of 70.76 is near median its 10-year median of 76.57. Over the past 10 years, this metric has ranged from a low of 62.23 to a high of 89.10. The Healthcare Providers & Services industry median Days Sales Outstanding is 47.19. Resonance Health's value of 70.76 is 49.9% above this industry median. Based on the distribution chart, Resonance Health ranks #509 out of 655 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Resonance Health's Days Sales Outstanding compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #509 out of 655 companies for Days Sales Outstanding. This places Resonance Health in the lower half of its industry. The industry median Days Sales Outstanding is 47.19. Resonance Health's value of 70.76 is 49.9% above this benchmark. Historically, Resonance Health's own Days Sales Outstanding has ranged from 62.23 to 89.10 over the past decade. While the company's 10-year median is 76.57 vs. the industry median of 47.19, Resonance Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 47.19, based on 655 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Days Sales Outstanding of 70.76 is 49.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 47.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Days Sales Outstanding is 70.76, which is near median its own 10-year median of 76.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 50.8% below its estimated fair value. The current Days Sales Outstanding is 70.76, which is near median its 10-year median of 76.57 and 49.9% above the Healthcare Providers & Services industry median of 47.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Days Sales Outstanding is 70.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
